Pharma BD Deal Intelligence
This transaction not only transforms our operations in the Australian market, but provides us with a beachhead in both Southeast Asia and South Africa... with…
iNova gives Valeant a regional commercial platform across Australia, NZ, SE Asia, and South Africa anchored by Duromine, Difflam, and Duro Tuss — established…
The bids rolling in for Valeant's Australian iNova subsidiary aren't quite up to expectations... Wells Fargo analyst David Maris sees it, 'this is another…
Source summaries from our enrichment pipeline; follow links for originals.
All 8 sources with sentiment breakdown →
Valeant acquired iNova Pharmaceuticals from Archer Capital and others for A$625M (~$625M USD) cash plus up to A$75M in milestones (~$700M total). Established Valeant's Australasia/SE Asia commercial platform.
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Valeant Pharmaceuticals International, Inc. / iNova Pharmaceuticals (this deal) | 2011 | $700M | 63 |
| Valeant Pharmaceuticals International, Inc. / Dow Pharmaceutical Sciences, Inc. | 2009 | $285M | 66 |
| Valeant Pharmaceuticals International, Inc. / Xcel Pharmaceuticals, Inc. | 2005 | $280M | 42 |
| Valeant Pharmaceuticals International, Inc. / Dermik Laboratories (Sanofi dermatology unit) | 2011 | $425M | 36 |
| Valeant Pharmaceuticals International, Inc. / Bausch + Lomb | 2013 | $8.7B | 36 |
| Valeant Pharmaceuticals International, Inc. / Medicis Pharmaceutical Corporation | 2012 | $2.6B | 33 |
| Valeant Pharmaceuticals International, Inc. / PreCision Dermatology, Inc. | 2014 | $475M | 23 |
← Browse all deals · How we score deals
More: 2011 deals · Valeant Pharmaceuticals International, Inc. deals · Dermatology deals